BioSpace News Archive

Kraig Biocraft Laboratories, Inc., announces that production of its BAM-1 spider silk hybrid strain continues to set records for silkworm size, growth, and robustness.

Akero Therapeutics, Inc. announced initiation of the SYNCHRONY Outcomes study, a Phase 3 trial evaluating the efficacy and safety of efruxifermin in patients with compensated cirrhosis, fibrosis stage 4 due to metabolic dysfunction-associated steatohepatitis.

Athira Pharma, Inc. announced that it has completed the first cohort of healthy volunteers in its ongoing, first-in-human, dose escalation Phase 1 clinical study evaluating ATH-1105, an oral, small molecule positive modulator of the neurotrophic hepatocyte growth factor system in development for the treatment of amyotrophic lateral sclerosis.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has approved Kevzara® for the treatment of patients weighing 63 kg or greater with active polyarticular juvenile idiopathic arthritis, a form of arthritis that impacts multiple joints at a time.

PepGen Inc. announced two executive team promotions effective immediately: Michelle Mellion, M.D., to Chief Medical Officer and Hayley Parker, Ph.D., to Senior Vice President, Global Regulatory Affairs.

Syntis Bio, Inc. announced its launch as a clinical-stage biopharmaceutical company with a mission to develop oral therapies that provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions.

Monopar Therapeutics Inc., a clinical-stage radiopharma company, and NorthStar Medical Radioisotopes, LLC, a global innovator in development and commercial production of medical radioisotopes, announced an amendment and expansion to their existing collaboration.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced a limited distribution agreement with THINK Surgical, Inc. regarding its wireless, handheld, TMINI Miniature Robotic System for total knee arthroplasty.

Eilean Therapeutics AU Pty Ltd has joined The Leukemia & Lymphoma Society in the groundbreaking collaborative Beat AML® Master Clinical Trial.

Cybin Inc., a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, has joined the Company as Senior Vice President, Clinical Development.